Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An indirect comparison to compare the efficacy of eltrombopag versus romiplostim
An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Eltrombopag & standard of care |
| ||
| Romiplostim & standard of care |
| ||
| Standard of care |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eltrombopag | Drug | Eltrombopag & standard of care |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Durable response: platelet count of >=50 and <400 Gi/L | 6 months | |
| Overall response: either a durable response or a transient platelet response | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Identified through a systematic review: TRA102537, Kuter 2008
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
Not provided
Not provided
| ID | Term |
|---|---|
| D013921 | Thrombocytopenia |
| ID | Term |
|---|---|
| D001791 | Blood Platelet Disorders |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D000095542 | Cytopenia |
Not provided
Not provided
| ID | Term |
|---|---|
| C520809 | eltrombopag |
| C488777 | romiplostim |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Romiplostim |
| Drug |
Romiplostim & standard of care |
|
| Placebo | Drug | Placebo & standard of care |
|